Time to remember to forget dose-intensification in lymphoma

Journal of Clinical Oncology

Volumn 29, Issue 30, 2011, Pages 3954-3956

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG MEGADOSE; EDITORIAL; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, B-CELL;

EID: 80054743181     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.5816     Document Type: Editorial

References (20)

1. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non- Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993 (Pubitemid 23095683)
2. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
3. Pfreundschuh M, Trümper L, Kloess M, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004 (Pubitemid 38970554)
4. Pfreundschuh MG, Ho A, Wolf M, et al.: Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an "equalizer"in the MInT (Mabthera International Trial Group) study. J Clin Oncol 23:567s, 2005 (abstr 6529)
5. Pfreundschuh M, Trümper L, Osterborg A, et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
6. Ohmachi K, Tobinai K, Kobayashi Y, et al.: Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: Final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol 22:1382-1391, 2011
7. Watanabe T, Tobinai K, Shibata T, et al.: Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol 29:3990-3998, 2011
8. Cunningham D, Smith P, Mouncey P, et al.: R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol 29:504s, 2011 (abstr 8000)
9. Schmitz N, Nickelsen M, Ziepert M, et al.: Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, highrisk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). J Clin Oncol 29:504s, 2011 (abstr 8002)
10. Stiff PJ, Unger JM, Cook J, et al.: Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol 29:504s, 2011 (abstr 8001)
11. Le Gouill S, Milpied NJ, Lamy T, et al.: First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. J Clin Oncol 29:504s, 2011 (abstr 8003)
12. Friedberg JW, Taylor MD, Cerhan JR, et al.: Follicular lymphoma in the United States: First report of the National Lympho Care study. J Clin Oncol 27:1202-1208, 2009
13. Federico M, Luminari S, Dondi A, et al.: R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage follicular lymphoma: Preliminary results of the FOLL05 IIL trial. Ann Oncol 22:129, 2011 (abstr 135)
14. Rummel MJ, Niederle N, Maschmeyer G, et al.: Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 114:168-169, 2009 (abstr 405)
15. Chen R, Gopal AK, Smith SE, et al.: Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin's lymphoma. Blood 116:128-129, 2010 (abstr 283)
16. Shustov A, Advani R, Bartlett NL, et al.: Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 116:423-424, 2010 (abstr 961)
17. Czuczman M, Johnson JL, Jung S-H, et al.: A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): initial report of CALGB study 50402. Ann Oncol 19:130, 2008 (abstr 143)
18. Grant BW, Leonard JP, Johnson JL, et al.: Combination biologic therapy as initial treatment for follicular lymphoma: Initial results from CALGB 50701 - A phase II trial of extended induction epratuzumab (anti-CD22) and rituximab (anti-CD20). Blood 116:191, 2010 (abstr 427)
19. Fowler N, Hagemeister F, McLaughlin P, et al.: Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-Hodgkin's lymphoma. Ann Oncol 22:128-129, 2011 (abstr 137)
20. Cheson BD, Friedberg JW, Kahl BS, et al.: Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lympoma Myeloma Leuk 10:452-457, 2010